A Phase II Study Of OSI-774 (NSC 718781) [erlotinib] Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer

Trial Profile

A Phase II Study Of OSI-774 (NSC 718781) [erlotinib] Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Carboplatin (Primary) ; Erlotinib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Updated from National Cancer Institue of Canada site.
    • 04 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top